Table 4.
Univariate analysis of overall survival in all patients.
| Variables | OS | |
|---|---|---|
| HR (95% CI) | P value | |
| Gender (Male vs Female) | 0.730 (0.387-1.379) | 0.332 |
| Age (<60 vs ≥60) | 0.624 (0.355-1.096) | 0.101 |
| Histology (Squamous NSCLC vs Non-squamous NSCLC vs Small cell lung cancer) | 1.213 (0.576-2.554) | 0.612 |
| Smoking status (Never vs Former or current) | 1.385 (0.387-1.379) | 0.025* |
| PD-L1 expression (<1% vs ≥1% vs NA) | 1.206 (0.620-2.343) | 0.581 |
| SUVmax | 1.059 (1.005-1.117) | 0.033* |
| SUVmaxwb | 1.010 (0.998-1.022) | 0.119 |
| SUVpeak | 1.030 (0.975-1.089) | 0.293 |
| SUVmean | 1.077 (0.920-1.261) | 0.357 |
| SUVmeanwb | 0.998 (0.881-1.131) | 0.981 |
| MTV | 1.000 (0.997-1.002) | 0.864 |
| MTVwb | 0.999 (0.881-1.131) | 0.486 |
| TLG | 1.000 (0.998-1.003) | 0.987 |
| TLGwb | 1.000 (0.999-1.000) | 0.906 |
| LDH,U/L | 1.003 (1.000-1.005) | 0.049* |
| Absolute platelet count,×109/L | 0.999 (0.996-1.003) | 0.660 |
| Absolute neutrophil count,×109/L | 0.968 (0.850-1.103) | 0.628 |
| Albumin levels, g/L | 0.968 (0.900-1.040) | 0.374 |
| dNLR | 0.974 (0.791-1.199) | 0.803 |
HR, hazard ratio; NSCLC non‒small-cell lung cancer; PD-L1, programmed death ligand 1, was acquired by immunohistochemistry; NA, not available; SUVmax maximum standardized uptake value; SUVpeak peak standardized uptake value; SUVmean mean standardized uptake value; MTV metabolic tumor volume; TLG total lesion glycolysis; SUVmaxwb whole-body maximum standardized uptake value; SUVmeanwb whole-body mean standardized uptake value; MTVwb, whole-body metabolic tumor volume; TLGwb, whole-body total lesion glycolysis; LDH lactate dehydrogenase; dNLR was defined as absolute neutrophil count/[white blood cell concentration − absolute neutrophil count]; OS, overall survival;* p<0.05.